Pulmonary hypertension developed in two women who had been taking fenfluramine for over eight months for weight reduction. On withdrawing the drug symptoms and electrocardiographic evidence of pulmonary hypertension disappeared in both cases. In one patient, however, the evidence recurred after rechallenge with fenfluramine.
pain and by the time of admission was unable to walk more than 50 m on the flat. In 1964 and 1969 she had been admitted for diarrhoea secondary to chronic ulcerative pancolitis and since then had received courses of iron for recurrent anaemia. For nine months before admission she had been taking fenfluramine 160 mg daily, having completed an 18-month course only six months before the start of the second course. One month before-that is, about four weeks after her symptoms began-she had also started an oral contraceptive (norethisterone 1 mg and mestranol 0 05 mg per tablet). She had not taken any oestrogen or progesterone preparation before.
On admission she weighed 61 kg and had bilateral ankle oedema. Jugular venous pressure was raised 3 cm and a right ventricular heave was noted. The pulmonary second sound was greatly accentuated, and a soft ejection systolic murmur was audible at the lower left sternal edge. The electrocardiogram showed right axis deviation with P pulmonale and changes compatible with right ventricular hypertrophy and strain (fig 1) . A chest x-ray picture showed prominence of the main pulmonary arteries but the heart shadow was normal. Lung volume measurements were normal but the TCLO was reduced to 5 01 mmol/min/kPa (14 96 ml/min/mm Hg) (predicted normal 8-79 ±1 44 mmol/min/kPa; 26-24 ±4 30 ml/min/mm Hg). A perfusion lung scan using 99mTc macroaggregates and a ventilation scan using 33Xe were normal. Right heart catheterisation showed the pulmonary artery pressure to be raised at 50/20 (mean 32) mm Hg, but the mean "wedge" pressure was only 9 mm Hg. Pulmonary angiography showed slight enlargement of the main pulmonary arteries with possible exaggerated tapering of the pulmonary vasculature but with no abrupt vessel cut-off.
Fenfluramine and the oral contraceptive were stopped and she was given thiazide diuretics. Three weeks later her symptoms had disappeared and she was able to go dancing. The pulmonary second heart sound was less accentuated and no cardiac murmurs were audible. One year after presentation her chest x-ray picture had returned to normal and the electrocardiogram was within normal limits (fig 1) . Repeat right heart catheterisation showed a pulmonary artery pressure of 19/5 (mean 11) mm Hg. 2) were normal. The serum thyrotrophin concentration 881 was raised at 16 mU/l and she had circulating thyroid antibodies.
Thyroxine was started and increased to 0-2 mg daily, together with a carbohydrate-restricted diet. She did not lose weight, however, and by April 1979 weighed 100 2 kg. Fenfluramine was then prescribed and increased to 120 mg daily, and by October her weight had fallen to 90 7 kg. In December-35 weeks after starting fenfluramine-she noticed increased exertional breathlessness and palpitations, and by January 1980 she was unable to walk further than 20 m on the flat.
Discussion
In 1967 the incidence of progressive pulmonary vascular hypertension suddenly increased in Switzerland, Germany, and Austria.3 Out of 40 patients studied in Basle, 32 had been taking a newly released anorectic drug, aminorex fumarate,4 and the absence of the usual causes of pulmonary vascular disease suggested that the pulmonary hypertension was drug induced. The incidence of the disease closely followed sales figures for the drug, and aminorex was withdrawn. A similar association has been suggested for the related compound chlorphentermine,6 and pulmonary hypertension has been reported in two obese patients taking phenformin7 and six women taking oral contraceptives. related to the other anorectic agents and, like aminorex and chlorphentermine, raises pulmonary diastolic pressure when infused acutely into dogs. 9 There are no reports of fenfluramine causing pulmonary hypertension in man, and six patients receiving the drug for up to three months had normal pulmonary artery pressures.'0 Primary pulmonary hypertension is a progressive disorder which is usually fatal in two to eight years. Reports of unexplained reversal are rare." In our first patient, who was not obese, the circumstantial evidence strongly implicated fenfluramine. Her symptoms predated taking the oral contraceptive, though the process may have been accelerated by its introduction. She had no evidence of thromboembolic disease, and reversal of the pulmonary hypertension coincided with the administration of a diuretic and withdrawal of fenfluramine.
In the second patient, who also developed pulmonary hypertension while taking fenfluramine and improved on stopping the drug, we could not incriminate fenfluramine with certainty. Pulmonary arterial hypertension may be due to increased pulmonary vascular resistance or may be a passive response to raised left atrial pressure, with normal or even low pulmonary vascular resistance, as in many cases of mitral regurgitation. In this case pulmonary vascular resistance was greatly increased. While this could be due to an effect of fenfluramine on the pulmonary vessels, it might also be explained as a secondary effect of left ventricular failure due to the mild systemic hypertension present. Increased left ventricular end-diastolic pressure to 25 mm Hg or more is often accompanied by modest increases in pulmonary vascular resistance (200-300 dyn-s-cm-).12 In this patient, however, pulmonary vascular resistance was greatly increased (440), with a left ventricular end-diastolic pressure of only 18 mm Hg. Also, despite effective treatment of the hypertension with a diuretic she again developed symptoms and electrocardiographic evidence of pulmonary hypertension on rechallenge with fenfluramine. This evidence suggests that the reversible component of her pulmonary hypertension was due to fenfluramine.
Fenfluramine is an effective antiobesity agent with mild hypoglycaemic properties.13 14 Hence, particularly when given to obese diabetics, drug treatment may be recommended for more than six months. Administration for six months produces weight loss in many patients but on drug withdrawal a gain in weight is the rule. 15 The hazards of prolonged use of fenfluramine remain to be evaluated. Pulmonary hypertension is the most serious to date, and we recommend that patients taking fenfluramine should be advised to report immediately any deterioration in exercise tolerance.
